256 related articles for article (PubMed ID: 29204662)
1. Vasopressors for acute myocardial infarction complicated by cardiogenic shock.
Prondzinsky R; Hirsch K; Wachsmuth L; Buerke M; Unverzagt S
Med Klin Intensivmed Notfmed; 2019 Feb; 114(1):21-29. PubMed ID: 29204662
[TBL] [Abstract][Full Text] [Related]
2. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial.
; Alexander JH; Reynolds HR; Stebbins AL; Dzavik V; Harrington RA; Van de Werf F; Hochman JS
JAMA; 2007 Apr; 297(15):1657-66. PubMed ID: 17387132
[TBL] [Abstract][Full Text] [Related]
3. Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction.
Levy B; Clere-Jehl R; Legras A; Morichau-Beauchant T; Leone M; Frederique G; Quenot JP; Kimmoun A; Cariou A; Lassus J; Harjola VP; Meziani F; Louis G; Rossignol P; Duarte K; Girerd N; Mebazaa A; Vignon P;
J Am Coll Cardiol; 2018 Jul; 72(2):173-182. PubMed ID: 29976291
[TBL] [Abstract][Full Text] [Related]
4. Inotropic Agents and Vasopressors in the Treatment of Cardiogenic Shock.
Shabana A; Dholoo F; Banerjee P
Curr Heart Fail Rep; 2020 Dec; 17(6):438-448. PubMed ID: 33103204
[TBL] [Abstract][Full Text] [Related]
5. Vasopressor use in cardiogenic shock.
Levy B; Klein T; Kimmoun A
Curr Opin Crit Care; 2020 Aug; 26(4):411-416. PubMed ID: 32487842
[TBL] [Abstract][Full Text] [Related]
6. Tilarginine in patients with acute myocardial infarction and cardiogenic shock.
Teerlink T
JAMA; 2007 Sep; 298(9):971-2; author reply 972-3. PubMed ID: 17785640
[No Abstract] [Full Text] [Related]
7. Cardiogenic shock: Inotropes and vasopressors.
Amado J; Gago P; Santos W; Mimoso J; de Jesus I
Rev Port Cardiol; 2016 Dec; 35(12):681-695. PubMed ID: 27836218
[TBL] [Abstract][Full Text] [Related]
8. Tilarginine in patients with acute myocardial infarction and cardiogenic shock.
Kielstein JT; Sydow K; Thum T
JAMA; 2007 Sep; 298(9):971; author reply 972-3. PubMed ID: 17785641
[No Abstract] [Full Text] [Related]
9. The medical treatment of cardiogenic shock: cardiovascular drugs.
De Backer D; Arias Ortiz J; Levy B
Curr Opin Crit Care; 2021 Aug; 27(4):426-432. PubMed ID: 33797431
[TBL] [Abstract][Full Text] [Related]
10. Dopamine versus norepinephrine as the first-line vasopressor in the treatment of cardiogenic shock.
Na SJ; Yang JH; Ko RE; Chung CR; Cho YH; Choi KH; Kim D; Park TK; Lee JM; Song YB; Choi JO; Hahn JY; Choi SH; Gwon HC
PLoS One; 2022; 17(11):e0277087. PubMed ID: 36327286
[TBL] [Abstract][Full Text] [Related]
11. Scandinavian SSAI clinical practice guideline on choice of first-line vasopressor for patients with acute circulatory failure.
Møller MH; Claudius C; Junttila E; Haney M; Oscarsson-Tibblin A; Haavind A; Perner A
Acta Anaesthesiol Scand; 2016 Nov; 60(10):1347-1366. PubMed ID: 27576362
[TBL] [Abstract][Full Text] [Related]
12. Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.
Avni T; Lador A; Lev S; Leibovici L; Paul M; Grossman A
PLoS One; 2015; 10(8):e0129305. PubMed ID: 26237037
[TBL] [Abstract][Full Text] [Related]
13. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction.
Geppert A; Dorninger A; Delle-Karth G; Zorn G; Heinz G; Huber K
Crit Care Med; 2006 Aug; 34(8):2035-42. PubMed ID: 16775569
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dopamine and norepinephrine in shock.
Lee J
N Engl J Med; 2010 Jun; 362(24):2328-9; author reply 2330-1. PubMed ID: 20560159
[No Abstract] [Full Text] [Related]
15. Vasopressor agents in shock.
Moyer JH; Mills LC
Am J Nurs; 1975 Apr; 75(4):620-5. PubMed ID: 1039254
[TBL] [Abstract][Full Text] [Related]
16. Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery.
Katz JN; Stebbins AL; Alexander JH; Reynolds HR; Pieper KS; Ruzyllo W; Werdan K; Geppert A; Dzavik V; Van de Werf F; Hochman JS;
Am Heart J; 2009 Oct; 158(4):680-7. PubMed ID: 19781431
[TBL] [Abstract][Full Text] [Related]
17. Inotropes and vasopressors use in cardiogenic shock: when, which and how much?
Levy B; Buzon J; Kimmoun A
Curr Opin Crit Care; 2019 Aug; 25(4):384-390. PubMed ID: 31166204
[TBL] [Abstract][Full Text] [Related]
18. Vasopressors and Inotropes in Acute Myocardial Infarction Related Cardiogenic Shock: A Systematic Review and Meta-Analysis.
Karami M; Hemradj VV; Ouweneel DM; den Uil CA; Limpens J; Otterspoor LC; Vlaar AP; Lagrand WK; Henriques JPS
J Clin Med; 2020 Jun; 9(7):. PubMed ID: 32629772
[TBL] [Abstract][Full Text] [Related]
19. Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction.
Jolly S; Newton G; Horlick E; Seidelin PH; Ross HJ; Husain M; Dzavik V
Am J Cardiol; 2005 Dec; 96(12):1617-20. PubMed ID: 16360345
[TBL] [Abstract][Full Text] [Related]
20. Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and long-term survival.
Antoniucci D; Valenti R; Santoro GM; Bolognese L; Trapani M; Moschi G; Fazzini PF
J Am Coll Cardiol; 1998 Feb; 31(2):294-300. PubMed ID: 9462570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
